Paxlovid

Pharma

Pfizer unveils 2026 guidance, triggering 5% share-price decline

With COVID sales falling and patent protections expiring, Pfizer is forecasting its 2026 revenue to be in the range of $59.5 billion to $62.5 billion.

Kevin Dunleavy Dec 16, 2025 11:19am

Pfizer's COVID products deliver Q4 sales gains

Feb 4, 2025 12:03pm

Pfizer, BMS and more start 2025 with drug price hikes: report

Jan 2, 2025 10:42am

As sales soared industrywide in Q3, Pfizer claimed No. 1 spot

Nov 25, 2024 3:00am

Pfizer cranks up revenue outlook amid Paxlovid sales bump

Oct 29, 2024 10:40am

Dupixent takes pharma DTC top spot in September

Oct 7, 2024 10:00am